Typewriter Therapeutics
PrivateLast Round
Series A
Sep 2, 2026
Total Funding Raised
$61M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Typewriter Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A round in September 2026.
Typewriter Therapeutics is a biotechnology company that is developing a ribonucleic acid (RNA) based gene writing therapeutic platform for the targeted insertion of therapeutic genes to treat severe genetic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Typewriter Therapeutics Comparables
Compare Typewriter Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Averna Therapeutics | 84% | |
| Tessera Therapeutics | 81% | |
| Integra Therapeutics | 80% |
For institutional investors. Book with your work email.
Typewriter Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 2, 2026 | ||||
| Grant | Dec 22, 2024 | ||||
| Seed | Feb 27, 2024 |
For institutional investors. Book with your work email.
Typewriter Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Agency for Medical Research and Development | Grant |
| RA Capital Management | Seed, Series A |
| Plug and Play Tech Center | Series A |
| ANRI株式会社 | Seed, Series A |
| AN Venture Partners | Seed, Series A |
| SBI Holdings | Series A |
| Gemseki Investment Inc. | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 17, 2026
Grew 23% QoQ, from 31 to 38 employees.
- Sep 2, 2026
$56M round led by AN Venture Partners and RA Capital Management.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 30, 2026
Typewriter emerged from stealth with $56M to develop an RNA-based gene insertion platform using retrotransposons to address limitations of conventional gene therapy in New York on Sep 30th '26.
- is_developingSep 3, 2026
On Sep 2nd '26, Typewriter is developing RNA medicines that could insert therapeutic genes directly into patients’ cells for in vivo CAR T medicines and genetic liver diseases in Massachusetts and Japan; its platform is preclinical, with first nonhuman-primate studies planned for late 2026.
- is_developingSep 3, 2026
Typewriter emerges from stealth with a $56M Series A to develop an all-RNA, non-viral gene-insertion platform for in vivo CAR T medicines and genetic liver diseases; AN Venture Partners and RA Capital Management lead the financing, the platform remains preclinical, and the company plans its first nonhuman-primate studies for late 2026 in Massachusetts and Japan.
- receives_financingSep 3, 2026
Typewriter received $56M in Series A financing led by AN Venture Partners and RA Capital Management, with participation from ANRI, Gemseki, and SBI US Gateway Fund, to pursue in vivo CAR T medicines, announced in Massachusetts and Japan on Sep 2nd '26.
- hiresSep 2, 2026
Typewriter announces the appointment of former Pfizer Chief Scientific Officer Mikael Dolsten, MD, PhD, as an independent director on Sep 2nd '26 in Massachusetts.
For institutional investors. Book with your work email.
Typewriter Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Typewriter Therapeutics's valuation, stock price, and market status.
Is Typewriter Therapeutics a public or private company?
Typewriter Therapeutics is a private company.
What is the current stock price of Typewriter Therapeutics?
Typewriter Therapeutics is a private company, so its shares have no public market price. Caplight tracks Typewriter Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Typewriter Therapeutics worth (valuation)?
Valuation information for Typewriter Therapeutics is not publicly available.
Can I buy Typewriter Therapeutics stock?
Typewriter Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Typewriter Therapeutics's last funding round?
Typewriter Therapeutics's most recent funding round was Series A on September 2, 2026.
Who are the main investors in Typewriter Therapeutics?
Key investors in Typewriter Therapeutics include RA Capital Management, AN Venture Partners.
Will Typewriter Therapeutics IPO soon?
No public IPO plans have been announced for Typewriter Therapeutics.
How can I track Typewriter Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Typewriter Therapeutics's shares on secondary markets.